Ezetimibe: A Selective Cholesterol Absorption Inhibitor

Edith A. Nutescu, Pharm.D.; Nancy L. Shapiro, Pharm.D.


Pharmacotherapy. 2003;23(11) 

In This Article

Formulary Considerations

Since ezetimibe is the first agent of a novel class of selective cholesterol absorption inhibitors, and in light of its benefits -- limited drug interactions, excellent safety profile, ease of dosing, and minimal laboratory monitoring, allowing more patients to reach their LDL goal -- its addition to formularies should be considered. Ezetimibe is supplied as 10-mg, white, capsule-shaped tablets; the average wholesale price is $72.38 for 30 tablets.[58] The combination of ezetimibe with a statin at a reduced dose may allow for a drug regimen comparable in price to that of a maximal dose of a statin alone ( Table 3 ). Cost-effectiveness also will depend on institution-specific contract pricing; therefore, additional pharmacoeconomic analyses of this combination are warranted.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.